Across TCGA pan-cancer cohorts, MIR487B Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated MIR487B data layer compared with 10 for mass-spec protein.
The strongest signal is observed in skin cutaneous melanoma (SKCM), where higher MIR487B Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated MIR487B expression acts as an unfavorable survival marker.
SKCM are the cancer types where MIR487B Mutation most reproducibly stratifies survival.